title: Latent Mycobacterium tuberculosis infection.
authors.forename: Haileyesus
authors.initials: H
authors.lastname: Getahun
authors.forename: Alberto
authors.initials: A
authors.lastname: Matteelli
authors.forename: Richard E
authors.initials: RE
authors.lastname: Chaisson
authors.forename: Mario
authors.initials: M
authors.lastname: Raviglione
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D055985:Latent Tuberculosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D009169:Mycobacterium tuberculosis; D017410:Practice Guidelines as Topic; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives; D012307:Risk Factors
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; C018421:rifapentine